Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy

Trial Profile

A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Avelumab (Primary) ; Ilixadencel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILIAD
  • Sponsors Immunicum
  • Most Recent Events

    • 11 Feb 2019 According to an Immunicum media release, for phase II part, ilixadencel will be combined with avelumab (Bavencio) which will be supplied by Merck KGaA, Darmstadt, Germany, and Pfizer under a collaboration agreement.
    • 11 Feb 2019 According to an Immunicum media release, the principal and coordinating investigator for the study is Dr. J. Weiss, Associate Professor of Medicine at the School of Medicine at University of North Carolina-Chapel Hill.
    • 11 Feb 2019 According to an Immunicum media release, the company will report after each dosing group is completed and expect to have the first announcement related to the trial in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top